Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers

ConclusionThis is the largest investigation of thePIK3R1 mutational landscape in breast cancer patients (n  = 6,009).PIK3R1 mutations were more common in triple-negative breast cancer (~  6%) than in HER2 + or HER2-/HR + disease (approximately 2%). While alterations in the PI3K/AKT pathway are often actionable in HER2-/HR + breast cancer, our study suggests thatPIK3R1 could be an important target in TNBC as well.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research